<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02909478</url>
  </required_header>
  <id_info>
    <org_study_id>GIHSYSU12</org_study_id>
    <nct_id>NCT02909478</nct_id>
  </id_info>
  <brief_title>Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer</brief_title>
  <official_title>Steroid-free Regimen With Aprepitant in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer Receiving FOLFOX Chemotherapy: a Randomized Phase 3 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Addition of aprepitant, an NK1 receptor antagonist to a 5-HT3 receptor antagonist and&#xD;
      dexamethasone regimen was shown to be effective for prevention of chemotherapy-induced nausea&#xD;
      and vomiting (CINV) with moderately emetogenic chemotherapy (MEC). Little is known about the&#xD;
      efficacy of aprepitant when used without dexamethasone. Dexamethasone is widely used to&#xD;
      prevent both acute and delayed nausea and vomiting induced by chemotherapy. However,&#xD;
      multi-period use of dexamethasone could be associated with side effect, such as&#xD;
      hyperglycemia, dyspepsia and insomnia. This randomized phase III trial studies antiemetic&#xD;
      therapy with aprepitant and tropisetron to see how well they work compared to dexamethasone&#xD;
      plus tropisetron in preventing chemotherapy-induced nausea and vomiting in patients with&#xD;
      colorectal cancer receiving FOLFOX(oxaliplatin, leuvovorin and 5-fluorouracil) chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 23, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response</measure>
    <time_frame>Day 1 to Day 5 after chemotherapy</time_frame>
    <description>No emetic episodes and no use of rescue medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nausea score</measure>
    <time_frame>Day 1 to Day 5 after chemotherapy</time_frame>
    <description>Nausea scores measured by the Nausea and Vomiting Daily Diary/Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Vomiting Episode or Use of Rescue Medication</measure>
    <time_frame>Day 1 to Day 5 after chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of rescue medication</measure>
    <time_frame>Day 1 to Day 5 after chemotherapy</time_frame>
    <description>Patients were asked to record daily number of extra nausea/vomiting pills taken because they developed nausea/vomiting in the following categories: None, One, Two, More than two in Nausea and Vomiting Daily Diary Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response in the acute phase (0-24 hours)</measure>
    <time_frame>0 to 24 hours after chemotherapy</time_frame>
    <description>No emetic episodes and no use of rescue medication in the acute phase (0-24 h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response in the delay phase (25 hours-120 hours)</measure>
    <time_frame>Day 2 to Day 5 (25 hours-120 hours) after chemotherapy</time_frame>
    <description>No emetic episodes and no use of rescue medication in the delay phase</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">315</enrollment>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Aprepitant arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aprepitant + Tropisetron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone+ Tropisetron</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant+Tropisetron</intervention_name>
    <description>Patients will receive the chemotherapy drugs oxaliplatin,leucovorin and 5-fluorouracil as well as the following antiemetic drugs:&#xD;
aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus Tropisetron (5mg IV of day1)</description>
    <arm_group_label>Aprepitant arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone+Tropisetron</intervention_name>
    <description>Patients will receive the chemotherapy drugs oxaliplatin, leucovorin and 5-fluorouracil as well as the following antiemetic drugs:&#xD;
Dexamethasone (10 mg IV on day 1 and 5 mg IV days 2, 3) plus Tropisetron (5mg IV of day1)</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of colorectal cancer&#xD;
&#xD;
          -  No prior chemotherapy and scheduled to receive FOLFOX chemotherapy&#xD;
             (oxaliplatin,leucovorin and 5-fluorouracil)&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2&#xD;
&#xD;
          -  Laboratory index: Hemoglobin ≥ 90 g/L (No blood transfusion within 14 days), Absolute&#xD;
             Neutrophil Count ≥ 1.5×10^9/L, Platelet Count ≥ 75×10^9/L, Serum Bilirubin ≤ 1.5×ULN,&#xD;
             ALT and AST ≤ 3.0×ULN (without liver metastases), ALT and AST ≤ 5.0×ULN (with liver&#xD;
             metastases), Serum Creatinine ≤ 1×ULN, Endogenous Creatinine Clearance&gt;60ml/min&#xD;
&#xD;
          -  Be able to read, understand and complete the questionnaire and diary&#xD;
&#xD;
          -  Be able to understand the study procedures and sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with any other study medicine within 4 weeks before enrollment.&#xD;
&#xD;
          -  Nausea or vomiting ≤ 24 hours prior to registration&#xD;
&#xD;
          -  Ongoing emesis due to obstruction of digestive tract&#xD;
&#xD;
          -  Concurrent use of olanzapine, phenothiazine or amifostine&#xD;
&#xD;
          -  Female with pregnancy or lactation&#xD;
&#xD;
          -  Severe cognitive compromise&#xD;
&#xD;
          -  Known history of CNS disease (e.g. brain metastases, seizure disorder)&#xD;
&#xD;
          -  Concurrent abdominal radiotherapy&#xD;
&#xD;
          -  Chronic alcoholism&#xD;
&#xD;
          -  Known hypersensitivity to aprepitant, tropisetron, or dexamethasone.&#xD;
&#xD;
          -  Known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial&#xD;
             infarction within the previous six months.&#xD;
&#xD;
          -  History of uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Serious or uncontroled infection&#xD;
&#xD;
          -  Known active HIV, viral hepatitis or tuberculosis infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanhong Deng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gastrointestinal Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 19, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>July 24, 2021</last_update_submitted>
  <last_update_submitted_qc>July 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yanhong Deng</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Tropisetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

